Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
Iain B McInnesProton RahmanAlice B GottliebElizabeth C HsiaAlexa P KollmeierSoumya D ChakravartyXie L XuRamanand A SubramanianPrasheen AgarwalShihong ShengYusang JiangBei ZhouYanli ZhuangDésirée van der HeijdePhillip J MeasePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
In biologic-naive PsA patients, guselkumab provided sustained improvements across diverse manifestations and maintained a favorable risk-benefit profile through week 52.